The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) iviral nfection, COVID-19, is known to result in significant morbidity and mortality. Additional understanding of the mechanisms inflammatory cytokines contribute to clinical symptomatology and sequelae from COVID-19, has promise to inform therapeutic strategies for this disease.
In their 4th and final year of medical school at Icahn School of Medicine at Mount Sinai, Portal Program trainees, Daniel Leisman, MD, MSCR and Likas Ronner, MD, MSCR, conducted a systematic review and meta-analysis of COVID-19 studies published or posted as preprints between Nov 1, 2019, and April 14, 2020, in an effort to compare the levels of a specific inflammatory cytokine, interleukin-6 concentrations, in patients with severe or critical disease, compared to those observed in other inflammatory syndromes. Sharing this co-first author collaboration their work was published in The Lancet Respiratory Medicine in October of 2020.
Dr. Daniel Leisman and Dr. Lukas Ronner are each currently pursuing an Internal Medicine Residency at the MGH and University of Pennsylvania, respectively, two of the premier residency programs in Internal Medicine in the US.
